4 Occupations and Locations with an Increased Risk of Asbestos Exposure Manufacturing of Asbestos products Shipyard workers Navy veterans Miners and Drillmen Demolition Workers Railroad workers Construction (insulation) workers Maritime Workers Oil refinery Workers Power plants Automobile reapir Maintenance workers Steel mills Refineries Sand or abrasive manufacturers Paper Mills Drywall Removers
7 Epidemiology of Malignant Mesothelioma (MM) Peak Asbestos Consumption in Australia in 1975 (90% in asbestos cement industry) First documented MM case in Australia in 1947 The Incidence of Mesothelioma is expected to increase and peak ( between 2015 and 2020? or even later) Latency Period What about Asbestos present in the Society?
8 Naturally Occurring Asbestos in Eastern Australia Potential asbestos-bearing rocks account for about 0.2% of land area of eastern Australia Government authorities and private enterprise need to take geological factors into account to reduce the likelihood of unplanned disturbance of natural asbestos-bearing materials Hendricks M, Environ Geol 2009 M. Hendrickx Environ Geol 2009
9 Malignant Mesothelioma Rising Incidence cases/year in NSW cases in Australia
10 Continued Asbestos Exposure in the Third World
11 Pathogenesis Mesothelioma Asbestos Fibres: Size and Form related to Risk Chronic Inflammation (Genes) Latency Period Life Style? Virus? Immune System (Genes) Mutations Growth Factors Needed is catalogue of genomic changes!
12 Asbestos Exposure & Malignant Mesothelioma Risk Genes Lifestyle? Exposure: Environmental? Occupational What is the Psychological Burden of the Knowledge of Past Asbestos Exposure?
13 Malignant Mesothelioma Originates in the mesothelium surrounding lungs, heart and abdominal organs
14 Symptoms of Mesothelioma Shortness of Breath Pain/Tightness Chest Malaise Weight Loss Pleural Effusion Pleural Thickening Chest Wall invasion (peritoneum)
15 Diagnosis &Treatment of Mesothelioma Earlier Diagnosis may offer an Opportunity for Better Treatment Markers for Early Diagnosis? Pathological Diagnosis needed (expertise!) Radical Treatments better investigated Significant Expertise of Medical Team needed Oncology: High-Volume Institutions seem to perform better
16 Surgical resection in MM Goal of surgery in MM is to remove all gross disease Complete resection is impossible since neither an ExtraPleural Pneumonectomy (EPP) nor a Pleurectomy/Decortication(P/D) can eradicate all (microscopic) disease The decision to perform EPP or P/D is driven primarily by surgeon Flores, J Thor Cardiovasc Surg 2008
17 Retrospective analysis of 663 consecutive MM patients ( ) Operative mortality Local recurrence Distant recurrence Stage I EPP N=385 7% 33% 66% Overall Survival 14 months 5 year survival 12% 38 months P/D N=278 4% 65% 35% Stage II Stage III Stage IV 19 months 11 months 7 months Flores, J Thor Cardiovasc Surg 2008
18 UK MARS trial: Mesothelioma And Radical Surgery trial 670 pts 3 cycles induction chemotherapy R A N D O M I Z E EPP + Adjuvant RT No surgery Primary endpoint: Overall survival Secondary endpoint: QOL
19 Neo-adjuvant multimodality trials in MM: Chemo EPP +/-RT Chemo N # EPP RR PFS (mo) MST (mo) Weder 2004 Gem Cis X % Flores 2006 Gem Cis x % 19 Weder 2007 Gem Cis x NR Krug 2007 Pem Cis x %
20 Chemotherapy for Malignant Mesothelioma I Standard Treatment available Second-Line Treatment more frequently used Personalized Approaches urgently needed Significant Proportion of Elderly Patients (Adaptations needed) Duration of Therapy?
21 Pemetrexed + Cisplatin: Benchmark regimen for Malignant Mesothelioma PC C p Pts RR 41% 17% <0.001 MST 12.1 M 9.3 M TTP 5.7 M 3.9 M Vogelzang, JCO 2003
22 Chemotherapy for Malignant Mesothelioma II Single-Agent therapy? Biologicals? New Drug investigation is feasible in Mesothelioma National/International Cooperation (scheduling priorities) necessary
23 Combined Modality Therapy for MM Radical Surgery Preceded or Followed by Chemotherapy Followed by Radiotherapy Careful Staging/Prognostic Factors Careful Evaluation of Comorbidities/Cardiopulmonary Function Expertise/High-Volume Institutions
24 Radiotherapy for Malignant Mesothelioma Palliative role (drain ports, chest wall) Malignant Mesothelioma: sensitive to radiotherapy Technical Difficulties IMRT
25 Care for Mesothelioma Patients in Australia Urban vs Rural? High-Volume Institution? Multidisciplinary Team Decisions? Accessibility of Expensive Medication? Accessibility of Palliative Care?
26 Research into Cellular Characteristics of Disease HE-stain EGFR; 3+ A: Mesothelioma Standard Microscopy B: Mesothelioma Staining with Antibody
27 New Drugs in MM Biological agents Added to standard treatment Second-Line Treatment International Cooperation Priorities Pharma Industry High-Troughput Screening
28 Research/Education at the ADRI I Patterns of Care for Malignant Mesothelioma in Australia (diagnosis, treatment, rural vs urban etc.) Development of Guidelines for the treatment of Mesothelioma What are psychological consequences of knowledge being exposed to asbestos in the past?
29 Research/Education at the ADRI II Individualisation of treatment: Define upfront which patient is going to respond/benefit from treatment Tissue bank: Find clues for better treatment and prevention New drug development/screening Prevention through Education
Understanding Pleural Mesothelioma A guide for people with cancer, their families and friends Cancer information For information & support, call Understanding Pleural Mesothelioma A guide for people with
Should Lawyers Advise their Meso Clients on Treatment Options? By Roger G. Worthington, Esq. and Seth Davidson Roger Worthington has been representing asbestos victims since 1988. He founded the Mesothelioma
Global Cancer Facts & Figures 2nd Edition Estimated Number of New Cancer Cases by World Area, 2008* 15 14 9 17 16 12 10 3 13 7 6 5 11 20 2 1 19 8 21 4 18 Worldwide* 12,667,500 1 Eastern Africa (221,100)
Exhibit A Kane Legal Mesothelioma Handbook Volume No. 1 David Kane, R.Ph., J.D. Professor of Pharmacy Law, Rutgers University Table of Contents Section 1 History of Asbestos...2 Section 2 - What is Mesothelioma?...3
The Role of Clinical Practice Guidelines, Survivorship Care Plans, and Inter-sectoral Care in Cancer Rehabilitation Prof. Eva Grunfeld, MD, DPhil, FCFP Ontario Institute for Cancer Research/Cancer Care
E U R O P E A N J O U R NA L O F CA N C E R45 (2009) 228 247 available at www.sciencedirect.com journal homepage: www.ejconline.com New response evaluation criteria in solid tumours: Revised RECIST guideline
Special Section: Cancer in Children & Adolescents Overview The news of a cancer diagnosis is never welcome, but may be even more unexpected and difficult when the disease is diagnosed in a child or adolescent.
Embargoed until 00.01 hours Wednesay 14 January 2015 EMBARGOED UNTIL 00.01 HOURS WEDNESDAY 14 JANUARY 2015 Overcoming Cancer in the 21st Century With increased cancer risk awareness and better access to
Toxicology Page 1 of 6 Asbestos exposure and malignant mesothelioma of the tunica vaginalis testis: and review of the literature C Meisenkothen 1 *, MM Finkelstein 2,3 Abstract Introduction We aim to report
Cancer Treatment & Survivorship Facts & Figures 14-15 Estimated Numbers of Cancer Survivors by State as of January 1, 14 OR 185,73 CA 1,661,74 WA 332,9 NV 18, ID 66,6 UT 81,26 MT 52,3 WY 29,8 CO 211,67
1 ontrac@petermac Victorian Adolescent & Young Adult Cancer Service A practice framework for working with 15 25 year-old cancer patients treated within the adult health sector Dr Susan Palmer & Associate
# National Cancer Survivorship Initiative Supported Self-Management Workstream CANCER FOLLOW-UP: TOWARDS A PERSONALISED APPROACH TO AFTERCARE SERVICES A REVIEW OF CURRENT PRACTICE AND SELECTED INITIATIVES
BREATHE EASY HOW RADIOLOGY HELPS TO FIND AND FIGHT LUNG DISEASES TABLE OF CONTENTS 3 BREATHE EASY TABLE OF CONTENTS 4 INTRODUCTION: AN OVERVIEW OF CHEST IMAGING 9 CHAPTER 1: Lung imaging: the techniques
GASTROENTEROLOGY 2012;143:844 857 Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer DAVID A. LIEBERMAN,*
Information for people with Mesothelioma and their carers Compiled by Mavis Robinson MBE, RGN Mesothelioma 2005 Edition Introduction Mesothelioma This booklet is written in an attempt to give basic information
FIGHTING FOR YOU Asbestos and dust diseases The sad legacy of years of exposure to asbestos, both in commercial and industrial situations, and at home, has left a terrible number of South Australians either
Asbestos Illnesses INJURY & NEGLIGENCE Asbestos SPECIALISTS Illnesses Injury & Negligence I was totally satisfied with my solicitors service, it was First Class. Quote about Pannone part of Slater & Gordon,
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September
Epidemiology of Mesothelioma and Historical Background Abstract Mesothelioma is a new malignant disease strongly associated with exposure to amphibole asbestos exposure (amosite and crocidolite) environmentally
MAURICE BLACKBURN LAWYERS ASBESTOS DISEASES 02 MAURICE BLACKBURN YOU RE WORTH FIGHTING FOR. If you are hurt, injured, or are facing an unfair situation, you and your family shouldn t have to suffer. That
Setting Up a Radiotherapy Programme: Clinical, Medical Physics, Radiation Protection and Safety Aspects SETTING UP A RADIOTHERAPY PROGRAMME: CLINICAL, MEDICAL PHYSICS, RADIATION PROTECTION AND SAFETY ASPECTS
European Medicines Agency London, 30 May 2008 Doc. Ref. EMEA/CHMP/GTWP/60436/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON FOLLOW-UP OF PATIENTS ADMINISTERED WITH GENE THERAPY
Focus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012 Prostate Cancer: Should We Be Screening? INSIDE THIS ISSUE 2 Why the Controversy? 3 Active Surveillance 4 The Radical Prostatectomy
Eur Respir J 2002; 19: 464 468 DOI: 10.1183/09031936.02.00231802 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Regular follow-up after curative
HEALTH FOR ALL FACULTY OF HEALTH SCIENCES UNIVERSITY OF SOUTHERN DENMARK The Faculty of Health Sciences consists of eight departments: DEPARTMENT OF CLINICAL RESEARCH DEPARTMENT OF MOLECULAR MEDICINE DEPARTMENT
Preparing an estimate of the national pattern of exposure to asbestos in cases of malignant mesothelioma JULY 2008 Copyright Notice Commonwealth of Australia 2008 ISBN 978 0 642 32792 5 This work is copyright.
A P U B L I C P O L I C Y M O N O G R A P H Overview of Asbestos Claims Issues and Trends August 2007 American Academy of Actuaries Mass Torts Subcommittee Overview of Asbestos Claims Issues and Trends
Home Search Collections Journals About Contact us My IOPscience Heterogeneity of exposure and attribution of mesothelioma: Trends and strategies in two American counties This content has been downloaded